CD44细胞
癌症研究
磷酸蛋白质组学
癌症
MAPK/ERK通路
受体
表皮生长因子受体
生物
磷酸化
医学
细胞生物学
细胞
内科学
蛋白激酶A
蛋白质磷酸化
生物化学
作者
Stefan Weigand,Frank Herting,Daniela Maisel,Adam Nopora,Edgar Voß,Christoph Schaab,Martin Klammer,Andreas Tebbe
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2012-07-10
卷期号:72 (17): 4329-4339
被引量:37
标识
DOI:10.1158/0008-5472.can-12-0136
摘要
The cell surface glycoprotein CD44 plays an important role in the development and progression of various tumor types. RG7356 is a humanized antibody targeting the constant region of CD44 that shows antitumor efficacy in mice implanted with CD44-expressing tumors such as MDA-MB-231 breast cancer cells. CD44 receptor seems to function as the main receptor for hyaluronic acid and osteopontin, serving as coreceptor for growth factor pathways like cMet, EGFR, HER-2, and VEGFR and by cytoskeletal modulation via ERM and Rho kinase signaling. To assess the direct impact of RG7356 binding to the CD44 receptor, a global mass spectrometry-based phosphoproteomics approach was applied to freshly isolated MDA-MB-231 tumor xenografts. Results from a global phosphoproteomics screen were further corroborated by Western blot and ELISA analyses of tumor lysates from CD44-expressing tumors. Short-term treatment of tumor-bearing mice with RG7356 resulted in modifications of the MAPK pathway in the responsive model, although no effects on downstream phosphorylation were observed in a nonresponsive xenograft model. Taken together, our approach augments the value of other high throughput techniques to identify biomarkers for clinical development of targeted agents.
科研通智能强力驱动
Strongly Powered by AbleSci AI